Bionano Genomics 4,45USD +3,90USD +708,21%
Broadcast Time: 7:00A-9:00A PST | 10:00A-12:00P EST | 3:00P-5:00P GMT | 4:00P-6:00P CET
January 11 Constitutional Cytogenetics
January 12 Heme Malignancy
January 13 Solid Tumor
January 14 Complex Molecular Diagnostics
January 15 Bonus Session: COVID-19 Expert Panel w/Live Q&A
Broadcast Time: 7:00A-9:00A PST | 10:00A-12:00P EST | 3:00P-5:00P GMT | 4:00P-6:00P CET
January 11 – Constitutional Cytogenetics
January 12 – Heme Malignancy
January 13 – Solid Tumor
January 14 – Complex Molecular Diagnostics
January 15 – Bonus Session: COVID-19 Expert Panel w/Live Q&A
Die haben nächste Woche ein Event vom 11. Jan bis 15. Jan.
Die Woche ziehts nach unten, am Fr. kaufen sich Leute günstig ein,
nächste Woche gehts ab.
Ich bin seit 0.90 USD drin, ich warte
January 11 – Constitutional Cytogenetics
January 12 – Heme Malignancy
January 13 – Solid Tumor
January 14 – Complex Molecular Diagnostics
January 15 – Bonus Session: COVID-19 Expert Panel w/Live Q&A
https://twitter.com/bionanogenomics/status/1347228001725894657?s=21
That’s why you need to collect really high coverage. If you have a lot of data you can find variants present in a low fraction of the cells. #Saphyr can map a tumor at 1600x. With $PACB HiFi this would take weeks per tumor. That’s why long read seq isn’t used in the clinic.
https://twitter.com/bionanogenomics/status/1347227854522642439?s=21
People often ask why structural variants (SV) are so important and why $BNGO is laser focused on revolutionizing the way they are detected in the clinic. Doesn’t the success of $PACB and $ILMN show that sequencing and the small variants it detects are what matters?
https://twitter.com/bionanogenomics/status/1347213793827442690?s=21
Studies have shown that #Saphyr can detect all variants identified by CMA, karyotyping, and FISH combined in #leukemias. No sequencing platform like $ILMN or $PACB has shown to have that capability.
https://twitter.com/bionanogenomics/status/1347228351027576832?s=21
So to summarize all of this: it’s not $BNGO vs $PACB or $ILMN. They can do much that we can’t do and vice versa. It’s $BNGO vs many decades-old technologies used in thousands of clinics all around the world that sequencing has failed to replace, and #Saphyr can.
https://twitter.com/bionanogenomics/status/1347228614547308545?s=21
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Bionano also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering, to cover over-allotments, if any. All of the shares in the proposed offering are to be sold by Bionano.
Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering. BTIG, LLC is acting as the lead manager, and Ladenburg Thalmann & Co. Inc. and Maxim Group LLC are acting as the co-managers.
The shares are being offered pursuant to a "shelf" registration statement on Form S-3 (File No. 333-245762) previously filed on August 14, 2020 and declared effective by the Securities and Exchange Commission (SEC) on August 25, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at 212-667-8055, or by email at EquityProspectus@opco.com.
Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that Bionano has filed with the SEC that are incorporated by reference in the preliminary prospectus supplement and the accompanying prospectus, which provide more information about Bionano and the offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about Bionano’s expectations regarding the completion, timing and size of the public offering. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties associated with Bionano’s business and financial condition in general, including the risks and uncertainties described in Bionano’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC, and Bionano’s subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Bionano undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Bionano Genomics Announces Proposed Underwritten Public Offering of Common Stock
BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Bionano also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering, to cover over-allotments, if any. All of the shares in the proposed offering are to be sold by Bionano.
Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering. BTIG, LLC is acting as the lead manager, and Ladenburg Thalmann & Co. Inc. and Maxim Group LLC are acting as the co-managers.
https://ir.bionanogenomics.com
SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the pricing of its previously announced underwritten public offering of 29,016,393 shares of its common stock at a price to the public of $3.05 per share. The gross proceeds to Bionano from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $88.5 million. In addition, Bionano has granted the underwriters a 30-day option to purchase up to an additional 4,352,458 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares in the proposed offering are to be sold by Bionano. The offering is expected to close on January 12, 2021, subject to customary closing conditions.
Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering. BTIG, LLC is acting as the lead manager, and Ladenburg Thalmann & Co. Inc. and Maxim Group LLC are acting as the co-managers.......
https://ir.bionanogenomics.com/news-releases/
89 Mio. $ Offering
Das hier ein Offering kommen würde, dürfte jedem klar gewesen sein. Wenn man betrachtet, woher die Aktie kommt (von ~0,50$), dann sind die 3,05$ aus Angebotspreis gar nicht mal schlecht. Momentan hält sich die Aktie mit 4,23$ noch ausgesprochen gut über dem Angebotspreis der neuen Aktien, es scheint so, als würden die Käufer ihre neuen Aktien nicht sofort auf den Markt werfen.
- 29,5 Mio. neue Aktien zu je 3,05$
https://seekingalpha.com/news/...rops-21-after-pricing-stock-offering
Optionen
| Boardmail an "Vassago" |
Wertpapier: Bionano Genomics Inc |